Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
$10.93
$4.51
$20.20
$236.61M0.4162,237 shs171,500 shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.71
-2.3%
$1.70
$1.40
$7.88
$75.91M1.56341,468 shs72,074 shs
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
$0.55
-0.2%
$0.55
$0.22
$1.97
$30.32M1.031.88 million shs260 shs
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
$2.23
$2.22
$1.29
$3.65
$127.82M1.7724,253 shsN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
0.00%0.00%0.00%0.00%0.00%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
0.00%-1.44%+0.59%+8.23%-67.37%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
0.00%0.00%0.00%0.00%-55.36%
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.941 of 5 stars
2.02.00.00.03.32.51.3
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
2.0599 of 5 stars
3.20.00.04.20.01.70.6
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
0.00
N/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.00
Hold$2.0016.96% Upside
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
2.40
Hold$3.92613.29% Upside
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
0.00
N/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
$17.26M0.00N/AN/A$4.07 per share0.00
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.81 per shareN/A
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
$30.99M0.98N/AN/A$0.31 per share1.77
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
$160.27M0.80N/AN/A($3.08) per share-0.72
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
-$63.57M-$1.10N/AN/A-35.44%N/A-40.05%N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest EPIX, ADRO, TRIL, PRTK, and MRNS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q3 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.2430N/AN/AN/AN/AN/A
5/8/2025Q2 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.19-$0.14+$0.05-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
N/AN/AN/AN/AN/A
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/A
8.91
8.91
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
67.15
67.15
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
N/A
1.66
1.47
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
N/A
0.52
0.46
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82

Institutional Ownership

CompanyInstitutional Ownership
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
49.93%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
98.80%
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
53.60%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
87.15%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
15216.21 millionN/AOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5044.39 million37.51 millionOptionable
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
11055.22 million52.20 millionOptionable
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
26857.32 million52.74 millionOptionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

Recent News About These Companies

Trillium Therapeutics Stock Price History
TTI Consumer Power Tools, Inc. is Seeking an IP Paralegal
Advances in Drug Discovery & Development 2024
Cachet Bicycle shakes off COVID
BridgeBio raises $1.25bn, and other biotech financings
Ratio Therapeutics Raises $50M in Series B Financing
Leukemia Therapeutics Global Market Report 2023

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aduro Biotech stock logo

Aduro Biotech NASDAQ:ADRO

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

$1.71 -0.04 (-2.29%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.72 +0.01 (+0.58%)
As of 07/11/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Marinus Pharmaceuticals stock logo

Marinus Pharmaceuticals NASDAQ:MRNS

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Paratek Pharmaceuticals stock logo

Paratek Pharmaceuticals NASDAQ:PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

Trillium Therapeutics stock logo

Trillium Therapeutics NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.